EP312: QLD Lipid Meeting October 2023

Welcome to my podcast. I am Doctor Warrick Bishop, and I want to help you to live as well as possible for as long as possible. I’m a practising cardiologist, best-selling author, keynote speaker, and the creator of The Healthy Heart Network. I have over 20 years as a specialist cardiologist and a private practice of over 10,000 patients. Podcast Summary: EP312 - QLD Lipid Meeting October 2023 Introduction Dr. Warwick Bishop, a cardiologist, discusses highlights from the Queensland Lipid Group's annual meeting held October 20-21, 2023, featuring presentations from leading international and local experts. The episode covers cutting-edge developments in cholesterol management, lipid disorders, inflammation, and cardiac imaging, with a focus on practical applications for reducing cardiovascular disease risk. This comprehensive overview aims to share key clinical insights and emerging treatment options with healthcare professionals and health-conscious listeners. Key Takeaways: Inclisiran is a novel RNA-based therapy that specifically targets liver cells to increase LDL receptors, lowering cholesterol levels with a convenient dosing schedule of two initial injections 90 days apart, then every six months. High-risk patients often fail to reach appropriate LDL cholesterol targets within a year after cardiac events, highlighting the persistent challenge of cholesterol management and medication adherence. LP(a) (lipoprotein(a)) is an emerging cardiovascular risk factor with genetic components; testing costs approximately $60 out of pocket and should be considered for individuals with significant family history of premature coronary artery disease. The omega-3 index, measurable through a $100 blood test, is a significant predictor of sudden cardiac death, making it a valuable assessment for those seeking to optimize heart health through dietary intervention. Colchicine, traditionally used for gout, shows promise in reducing cardiovascular events by dampening the inflammasome, a molecular complex central to inflammation pathways. Current evidence on dietary inflammation is limited and not well-established; weight reduction and calorie control remain the only interventions with robust scientific support. Coronary artery calcium scoring blurs the line between primary and secondary prevention, as a score of 400 indicates risk equivalent to someone who has already experienced a coronary event. Mental health conditions show significant associations with diet and inflammation, suggesting an important intersection between psychiatry and cardiovascular risk management that warrants further investigation.